대한갑상선학회 갑상선분화암 진료권고안 2024 어떻게 바뀌었나: 진단부터 초기치료까지
Updates in the 2024 Korean Thyroid Association Clinical Practice Guidelines for Differentiated Thyroid Cancer: from Diagnosis to Initial Treatment
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The 2024 Korean Thyroid Association (KTA) Clinical Practice Guidelines for Differentiated Thyroid Cancer (DTC) introduce updated recommendations based on recent advancements and clinical evidence. These guidelines encompass a broad spectrum of DTC cases, from localized thyroid cancer to advanced, treatment-resistant cases, covering both diagnostic and therapeutic approaches. Given the extensive content, careful organization was essential to effectively communicate these updates to KTA members. This article reviews the key changes in the 2024 guidelines, with a focus on revised diagnostic criteria, risk stratification, and initial treatment protocols for DTC. Updates include improved approaches to risk assessment, refinements in surgical intervention guidelines. Additionally, the new guidelines emphasize personalized management strategies that account for individual patient risk profiles and molecular characteristics. These updates aim to enhance diagnostic accuracy, optimize treatment outcomes, and minimize overtreatment for low-risk patients, aligning Korean practices with global standards.
Abstract
The 2024 Korean Thyroid Association (KTA) Clinical Practice Guidelines for Differentiated Thyroid Cancer (DTC) introduce updated recommendations based on recent advancements and clinical evidence. These guidelines encompass a broad spectrum of DTC cases, from localized thyroid cancer to advanced, treatment-resistant cases, covering both diagnostic and therapeutic approaches. Given the extensive content, careful organization was essential to effectively communicate these updates to KTA members. This article reviews the key changes in the 2024 guidelines, with a focus on revised diagnostic criteria, risk stratification, and initial treatment protocols for DTC. Updates include improved approaches to risk assessment, refinements in surgical intervention guidelines. Additionally, the new guidelines emphasize personalized management strategies that account for individual patient risk profiles and molecular characteristics. These updates aim to enhance diagnostic accuracy, optimize treatment outcomes, and minimize overtreatment for low-risk patients, aligning Korean practices with global standards.
참고문헌 (19)
- Chen DW, "Thyroid cancer", Lancet, 401(10387), pp.1531~1544 (2023)
- Miranda-Filho A, "Thyroid cancer incidence trends by histology in 25 countries : a population-based study", Lancet Diabetes Endocrinol, 9(4), pp.225~234 (2021)
- Park EH, "Cancer statistics in Korea : incidence, mortality, survival, and prevalence in 2021", Cancer Res Treat, 56(2), pp.357~371 (2024)
- Kim WB, "Management guidelines for patients with thyroid nodules and thyroid cancer", J Korean Endocr Soc, 22(3), pp.157~187 (2007)
- Yi KH, "Revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer", Endocrinol Metab, 25(4), pp.270~297 (2010)
- Yi KH, "2016 Revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer", Int J Thyroidol, 9(2), pp.59~126 (2016)
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
- Park YJ, "Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; overview and summary 2024", Int J Thyroidol, 17(1), pp.1~20 (2024)
- Park YJ, "Korean Thyroid Association management guidelines for patients with thyroid nodules 2024", Int J Thyroidol, 17(1), pp.208~244 (2024)
- Lee JY, "Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers-Chapter 1. Preoperative imaging and diagnostic evaluation in thyroid cancer 2024", Int J Thyroidol, 17(1), pp.21~29 (2024)
- Ali SZ, "The 2023 Bethesda system for reporting thyroid cytopathology", J Am Soc Cytopathol, 12(5), pp.319~325 (2023)
- Cho YY, "Malignancy risk of follicular neoplasm(Bethesda IV)with variable cutoffs of tumor size : a systemic review and meta-analysis", J Clin Endocrinol Metab, 109(5), pp.1383~1392 (2024)
- Cho YY, "Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers-Chapter 2. Surgical management of thyroid cancer 2024", Int J Thyroidol, 17(1), pp.30~52 (2024)
- Ryu CH, "Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers-Chapter 3. Perioperative assessment of surgical complications 2024", Int J Thyroidol, 17(1), pp.53~60 (2024)
- Shin SJ, "Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers-Chapter 4. Pathological diagnosis and staging after thyroidectomy 2024", Int J Thyroidol, 17(1), pp.61~67 (2024)
- Lee EK, "Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers-Chapter 5. Evaluation of recurrence risk postoperatively and initial risk stratification in differentiated thyroid cancer 2024", Int J Thyroidol, 17(1), pp.68~96 (2024)
- Park S, "Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers-Chapter 6. Radioactive iodine treatment after thyroidectomy 2024", Int J Thyroidol, 17(1), pp.97~110 (2024)
- Park S, "Comparison of recombinant human thyroid-stimulating hormone and thyroid hormone withdrawal for 131 I therapy in patients with intermediate-to high-risk thyroid cancer : a systematic review and meta-analysis", Clin Nucl Med, 49(3), pp.e96~e104 (2024)
- Chong A, "Clinical implications of adding SPECT", CT to radioiodine whole-body scan in patients with differentiated thyroid cancer : a systematic review and meta-analysis, 2024, pp.49(3), 215~225